-DOCSTART- -X- O
Antibodies -X- _ O
are -X- _ O
an -X- _ O
important -X- _ O
component -X- _ O
in -X- _ O
host -X- _ O
immune -X- _ O
responses -X- _ O
to -X- _ O
viral -X- _ O
pathogens. -X- _ O
Because -X- _ O
of -X- _ O
their -X- _ O
unique -X- _ O
maturation -X- _ O
process -X- _ O
, -X- _ O
antibodies -X- _ O
can -X- _ O
evolve -X- _ O
to -X- _ O
be -X- _ O
highly -X- _ O
specific -X- _ O
to -X- _ O
viral -X- _ O
antigens. -X- _ O
Physicians -X- _ O
and -X- _ O
researchers -X- _ O
have -X- _ O
been -X- _ O
relying -X- _ O
on -X- _ O
such -X- _ O
high -X- _ O
specificity -X- _ O
in -X- _ O
their -X- _ O
quest -X- _ O
to -X- _ O
understand -X- _ O
hostâ€“viral -X- _ O
interaction -X- _ O
and -X- _ O
viral -X- _ O
pathogenesis -X- _ O
mechanisms -X- _ O
and -X- _ O
to -X- _ O
find -X- _ O
potential -X- _ O
cures -X- _ O
for -X- _ O
viral -X- _ B-Patient
infection -X- _ I-Patient
and -X- _ I-Patient
disease. -X- _ I-Patient
With -X- _ O
more -X- _ O
than -X- _ O
60 -X- _ B-Intervention
recombinant -X- _ I-Intervention
monoclonal -X- _ I-Intervention
antibodies -X- _ I-Intervention
developed -X- _ O
for -X- _ O
human -X- _ O
use -X- _ O
in -X- _ O
the -X- _ O
last -X- _ O
20 -X- _ O
years -X- _ O
, -X- _ O
monoclonal -X- _ B-Outcome
antibodies -X- _ I-Outcome
are -X- _ I-Outcome
now -X- _ I-Outcome
considered -X- _ I-Outcome
a -X- _ I-Outcome
viable -X- _ I-Outcome
therapeutic -X- _ I-Outcome
modality -X- _ I-Outcome
for -X- _ I-Outcome
infectious -X- _ I-Outcome
disease -X- _ I-Outcome
targets -X- _ I-Outcome
, -X- _ O
including -X- _ O
newly -X- _ O
emerging -X- _ O
viral -X- _ O
pathogens -X- _ O
such -X- _ O
as -X- _ O
Ebola -X- _ O
representing -X- _ O
heightened -X- _ O
public -X- _ O
health -X- _ O
concerns -X- _ O
, -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
pathogens -X- _ O
that -X- _ O
have -X- _ O
long -X- _ O
been -X- _ O
known -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
human -X- _ B-Patient
cytomegalovirus. -X- _ I-Patient
Here -X- _ O
, -X- _ O
we -X- _ O
summarize -X- _ O
some -X- _ O
recent -X- _ O
advances -X- _ O
in -X- _ O
identification -X- _ O
and -X- _ O
characterization -X- _ O
of -X- _ O
monoclonal -X- _ B-Intervention
antibodies -X- _ I-Intervention
suitable -X- _ O
as -X- _ O
drug -X- _ O
candidates -X- _ O
for -X- _ O
clinical -X- _ O
evaluation -X- _ O
, -X- _ O
and -X- _ O
review -X- _ O
some -X- _ O
promising -X- _ O
candidates -X- _ O
in -X- _ O
the -X- _ O
development -X- _ O
pipeline -X- _ O
. -X- _ O

